Co-Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study.

Chaugai S, Dickson AL, Shuey MM, Feng Q, Barker KA, Wei WQ, Luther JM, Stein CM, Chung CP
Clin Pharmacol Ther. 2019 105 (3): 703-709

PMID: 30223305 · PMCID: PMC6379114 · DOI:10.1002/cpt.1233

Tizanidine, a widely used muscle relaxant that can lower blood pressure, is metabolized by the cytochrome P450 1A2 (CYP1A2). We studied 1,626 patients prescribed tizanidine and 5,012 prescribed cyclobenzaprine concurrently with a strong CYP1A2 inhibitor. The primary outcome was severe hypotension, defined as systolic blood pressure (SBP) ≤ 70 mmHg during periods of drug co-exposure. Severe hypotension occurred more often in the tizanidine group (2.03%; n = 33) than the cyclobenzaprine group (1.28%; n = 64); odds ratio (OR) = 1.60; P = 0.029. This difference remained statistically significant after adjustment for a log-transformed propensity score that included age, sex, race, Charlson's comorbidity index, and concurrent use of antihypertensive medications (OR = 1.57; P = 0.049). A sensitivity analysis that defined hypotension as SBP < 90 mmHg also yielded higher rates of hypotension among patients prescribed tizanidine. In conclusion, CYP1A2 inhibition increases the risk of hypotensive episodes associated with the use of tizanidine in routine clinical practice.

© 2018 American Society for Clinical Pharmacology and Therapeutics.

MeSH Terms (15)

Adult Clonidine Cohort Studies Cytochrome P-450 CYP1A2 Cytochrome P-450 CYP1A2 Inhibitors Drug Therapy, Combination Female Humans Hypotension Male Middle Aged Muscle Relaxants, Central Polypharmacy Retrospective Studies Risk Factors

Connections (1)

This publication is referenced by other Labnodes entities: